John A. Taylor, III, MD, MS, discussed the new wealth of options in non–muscle invasive bladder cancer, specifically highlighting detalimogene voraplasmid.
John A. Taylor III, MD, MS
Advertisement
Articles by John A. Taylor III, MD, MS
"The efficacy findings reported to date are 71% any time response," says John A. Taylor III, MD, MS.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
3
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
4
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
5
